Tamura Takashi, Imai Jun, Tanimoto Masahiko, Matsumoto Akihiro, Suzuki Akira, Horikiri Yuji, Suzuki Takehiko, Yoshino Hiroyuki
DDS Research Department, Discovery Research Laboratory, Tanabe Seiyaku Co. Ltd., Osaka, Japan.
Eur J Pharm Biopharm. 2002 Mar;53(2):241-7. doi: 10.1016/s0939-6411(01)00244-2.
The aim of this study is to evaluate and compare the dissolution profiles of cisplatin-loaded microspheres (CDDP-MS) in vitro and in vivo, and to determine the relationship between the dissolution profiles in vitro and systemic toxicity. For this purpose, three types of CDDP-MS that release the CDDP for 1, 2 and 5 weeks without a large amount of initial release in phosphate buffered saline (pH 7.4) were prepared. The dissolution profiles of these formulations in vivo were well correlated with in vitro studies, and resulted in well-controlled plasma platinum concentration. The systemic toxicity of the CDDP-MS and CDDP dissolved in saline (CDDP-SOL) were assessed by intraperitoneal administration in mice. The maximal tolerable dose (MTD) of CDDP-SOL was 13.4 mg/kg, whereas the CDDP-MS of 1, 2 and 5-week types were 34.6, 44.2, 62.6 mg/kg, respectively. The MTD of CDDP increased proportionally when 50% of CDDP had been released from MS in vitro (MTD (mg/kg)=5.22 x T(50(day)) + 13.2, R(2)=0.9935). We demonstrate that the systemic toxicity of CDDP-MS can be predicted by evaluation of the dissolution rate in vitro since in vivo dissolution was correlated with the in vitro.
本研究的目的是评估和比较顺铂微球(CDDP-MS)在体外和体内的溶出曲线,并确定体外溶出曲线与全身毒性之间的关系。为此,制备了三种类型的CDDP-MS,它们在磷酸盐缓冲盐水(pH 7.4)中可在1、2和5周内释放顺铂,且无大量初始释放。这些制剂在体内的溶出曲线与体外研究具有良好的相关性,并导致血浆铂浓度得到良好控制。通过对小鼠进行腹腔给药来评估CDDP-MS和顺铂溶解于盐水中(CDDP-SOL)的全身毒性。CDDP-SOL的最大耐受剂量(MTD)为13.4 mg/kg,而1周、2周和5周类型的CDDP-MS分别为34.6、44.2、62.6 mg/kg。当50%的顺铂在体外从微球中释放时,顺铂的MTD成比例增加(MTD(mg/kg)=5.22×T(50(天))+13.2,R(2)=0.9935)。我们证明,由于体内溶出与体外溶出相关,因此通过评估体外溶出速率可以预测CDDP-MS的全身毒性。